Friday, July 28, 2017

US FDA News: Cyclobenzaprine HCl and Amantadine HCl by Apace Packaging: Recall - Potential Mislabeling

Unintentional dosing with Cyclobenzaprine HCl may potentially lead to the development of life-threatening serotonin syndrome, and other serious adverse events.
Read more: Cyclobenzaprine HCl and Amantadine HCl by Apace Packaging: Recall - Potential Mislabeling